Advertisement
AXON vs KROS
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Keros Therapeutics (KROS) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) is a profitable, high-growth public safety technology company, while Keros Therapeutics (KROS) is a pre-revenue, clinical-stage biopharmaceutical developer.
- AXON has posted nine consecutive quarters of roughly 30%-plus revenue growth, while KROS generates no recurring product revenue and relies on milestone-based partner payments.
- The two names carry sharply different risk profiles: AXON faces valuation and software-sector sentiment pressure, while KROS faces clinical and execution risk around its pipeline.
- Recent market activity has pressured both stocks, but AXON's pullback reflects sector multiple compression, whereas KROS reflects binary clinical milestones and uneven revenue recognition.
- Investors comparing the two are effectively weighing an established growth platform against a speculative biotech turnaround story.
Introduction
Comparing AXON and KROS highlights two very different investment profiles in the current market. Axon Enterprise is an established, profitable leader in public safety technology, while Keros Therapeutics is a clinical-stage biotechnology company with no marketed products. A growth-oriented investor focused on recurring revenue and expanding margins may find AXON more familiar, whereas a trader comfortable with binary, catalyst-driven risk may gravitate toward KROS. Understanding their relative performance, market positioning, and risk factors can help clarify which type of opportunity each stock represents.
AXON Overview and Recent Performance
Axon Enterprise develops and sells public safety technology, including TASER energy devices, body-worn and in-car cameras, drones, digital evidence management software, and AI-enabled tools such as its Draft One report-writing product. The company has increasingly shifted toward a software-as-a-service (SaaS) model, with software and services revenue and annual recurring revenue (ARR) growing rapidly in recent quarters.
Fundamental momentum has remained strong. Recent results have shown revenue growing at roughly 30% or more year over year, with net revenue retention (NRR, a measure of how much existing customers expand their spending) around 125%. Management has also raised its full-year revenue outlook, and future contracted bookings have climbed into the mid-teens of billions of dollars. Despite this, AXON shares have experienced volatility in recent weeks, reflecting broader software-sector multiple compression and investor concerns about valuation rather than deteriorating fundamentals.
KROS Overview and Recent Performance
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics that target dysfunctional signaling of the TGF-β (transforming growth factor-beta) family of proteins. Its lead wholly owned candidate, rinvatercept, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), while its most advanced candidate, elritercept, is partnered with Takeda for hematological disorders.
Because Keros has no marketed products, its revenue is driven almost entirely by license and milestone payments, making quarterly results highly uneven. Recent quarters have shown little or no revenue, wider-than-expected losses, and a share price that has declined substantially year to date. The company ended its most recent quarter with cash and cash equivalents around $258 million and expects its runway to fund operations into the first half of 2028, providing time to advance its clinical programs without immediate financing pressure.
Trending AI Robots
For traders looking to navigate comparisons like this systematically, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that monitor thousands of different tickers, but only the ones best suited to current market conditions earn a place in this curated section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, giving users access to a diverse range of automated approaches. Exploring the Trending AI Robots page can help traders identify the strategies currently demonstrating the strongest relative performance across the market.
Head-to-Head Comparison
The most fundamental contrast between AXON and KROS is business maturity. AXON operates a diversified hardware-plus-software ecosystem with recurring subscription revenue, expanding margins, and a large contracted backlog. KROS, by contrast, is pre-commercial and depends on clinical trial outcomes and milestone payments for any near-term revenue.
Growth drivers also differ sharply. AXON's momentum is tied to rising adoption of its AI-enabled software, counter-drone technology, and international and enterprise expansion. KROS's outlook hinges on clinical data readouts—particularly initial Phase 2 data for rinvatercept in DMD, expected in the first half of 2027—and on regulatory progress.
Risk factors diverge as well. AXON faces concentration in government budgets, premium valuation sensitivity, and competitive pressure from established public safety and defense vendors. KROS carries binary clinical risk, reliance on partner milestone economics, and competitive pressure from larger DMD-focused drug developers. On market sentiment, AXON has generally shown steadier institutional positioning despite a recent drawdown, while KROS has displayed more pronounced downside volatility and mixed insider activity.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue durability, and catalyst visibility, Tickeron's AI framework would likely favor AXON in the current environment. AXON demonstrates more stable fundamentals, recurring revenue growth, and a diversified product pipeline, which tend to produce a more consistent trend profile. KROS, while offering potentially significant upside tied to clinical catalysts, presents greater uncertainty around revenue timing and near-term momentum. The AI's assessment would therefore lean toward AXON for its relative positioning and stability, while recognizing that KROS remains a higher-risk, catalyst-dependent opportunity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and KROS is a StrongBuy.
AXON's RSI Indicator climbs out of oversold territory
The RSI Oscillator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 26 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 56 cases where AXON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.166) is normal, around the industry mean (4.854). AXON has a moderately high P/E Ratio (167.854) as compared to the industry average of (16.403). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
KROS sees its Stochastic Oscillator ascending out of oversold territory
On October 21, 2026, the Stochastic Oscillator for KROS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 49 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
KROS moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 227 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 193 of 226 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 76 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 29 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.858) is normal, around the industry mean (2.973). P/E Ratio (-3.525) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AXON | KROS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 70 | 100 | |
SMR RATING 1..100 | 81 | 95 | |
PRICE GROWTH RATING 1..100 | 63 | 57 | |
P/E GROWTH RATING 1..100 | 44 | 97 | |
SEASONALITY SCORE 1..100 | 85 | 35 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (27) in the null industry is somewhat better than the same rating for AXON (92) in the Biotechnology industry. This means that KROS’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as KROS (100) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as KROS (95) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
KROS's Price Growth Rating (57) in the null industry is in the same range as AXON (63) in the Biotechnology industry. This means that KROS’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for KROS (97) in the null industry. This means that AXON’s stock grew somewhat faster than KROS’s over the last 12 months.
| AXON | KROS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 89% |
| Momentum ODDS (%) | N/A | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 76% |
| Advances ODDS (%) | 1 day ago 74% | 3 days ago 77% |
| Declines ODDS (%) | 4 days ago 70% | 9 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while KROS’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- KROS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 2 bearish.
- KROS’s TA Score: 5 bullish, 3 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -0.62% price change this week, while KROS (@Biotechnology) price change was +2.25% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.31%. For the same industry, the average monthly price growth was -17.03%, and the average quarterly price growth was -18.12%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
AXON is expected to report earnings on Nov 03, 2026.
KROS is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Aerospace & Defense (-3.31% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KROS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | +1.52% | ||
| SANA - KROS | 48% Loosely correlated | +0.85% | ||
| ABEO - KROS | 44% Loosely correlated | -0.89% | ||
| AXON - KROS | 43% Loosely correlated | +2.98% | ||
| EDIT - KROS | 43% Loosely correlated | -0.80% | ||
| TSHA - KROS | 43% Loosely correlated | -2.79% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OSCV | 40.46 | 0.31 | +0.76% |
| Opus Small Cap Value ETF (OSCV) | |||
| DABS | 49.85 | 0.22 | +0.44% |
| Doubleline Asset-Backed Securities ETF | |||
| BCGD | 26.15 | -0.43 | -1.62% |
| Baron Global Durable Advantage ETF (BCGD) | |||
| RSPT | 63.95 | -1.51 | -2.31% |
| Invesco S&P 500 Equal Weight Technology ETF (RSPT) | |||
| BCEM | 24.48 | -0.80 | -3.16% |
| Baron Emerging Markets Select ETF (BCEM) | |||